Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 101-107

  Allegra, Alessandro ^a   Alonci, Andrea ^a   Bellomo, Giacomo ^a   Campo, Salvatore ^a   Cannavò, Antonino ^a   Penna, Giuseppa ^a   Russo, Sabina ^a   Centorrino, Raffaella ^a   Gerace, Demetrio ^a   Petrungaro, Annamaria ^a   Musolino, Caterina ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

essential thrombocythemia; JAK2 mutation; NGAL; P selectin; PMN activation; polycythemia vera; thombosis

Indexed keywords

CD11B ANTIGEN; JANUS KINASE 2; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PADGEM PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; THROMBOCYTE ACTIVATION; THROMBOCYTHEMIA; THROMBOSIS;

ACUTE-PHASE PROTEINS; AGED; BLOOD PLATELETS; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; JANUS KINASE 2; LIPOCALINS; MALE; MUTATION; NEUTROPHILS; POLYCYTHEMIA VERA; PROGNOSIS; PROTO-ONCOGENE PROTEINS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 78651316300     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.531413     Document Type: Article

References (44)

1. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-290.
2. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myelo-proliferative disorders. Leukemia 2008;22:905-914.
3. Cortelazzo SS, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
4. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and JAK2 mutation status. Blood 2007;109:2310-2313. (Pubitemid 46425868)
5. Landolfi R, Di Gennaro I, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446-2452.
6. Kundranda MN, Maiti B, Iqbal N, et al. The association of leukocytosis, thrombocytosis and JAK2V617F mutation with thrombotic events in myeloproliferative disorders (MPD's). Blood 2008;112(Suppl. 1):Abstract 2803.
7. Daanesh J, Collins R, Applebey P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-1482.
8. Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in healthy donors given granulocyte-colony stimulating factor. Blood 1999;93:2506-2514.
9. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Hematologica 2006;91:169-175.
10. Alvarez-Larran A, Garcia Pagan JC, Abraldes JG, et al. Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythe-mia vera. Br J Haematol 2004;124:329-335.
11. Triebel S, Blaser J, Reinke H, Tschesche H. A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 1992;314:386-388.
12. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary sequence of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268: 10425-10432.
13. Flower DR. The lipocalin family: structure and function. Biochem J 1996;318:1-14.
14. Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta 2000;1482:298-307.
15. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996;38:414-420.
16. Mori L, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005;115:610-621.
17. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231-1238.
18. Wagener G, Jan M, Kim M, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006;105:485-491.
19. Mishra J, Ma Q, Kelly C, et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 2006;21:856-863.
20. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer 1998;79:565-572.
21. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008;108:389-397.
22. Kubben FJ, Sier CF, Hawinkelas LJ, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autode-gradation and the impact for gastric cancer. Eur J Cancer 2007;43:1869-1876.
23. Zhang H, Xu L, Xiao D, et al. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol 2007;60:555-561.
24. Furutani M, Arii S, Mizumoto M, Kato M, Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett 1998;122:209-214.
25. Laurell H, Bouisson M, Berthelemy P, et al. Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J Gastroenterol 2006;12:3344-3351.
26. Friedl A, Stoesz SP, Buckley P, Gould MN. Neutrophil gelatinase- associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histo-chem J 1999;31:433-441.
27. Lim R, Ahmed N, Borregaard N, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer 2007;120:2426-2434.
28. Leng X, Lin H, Ding T, et al. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene 2008;27:6110-6119.
29. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34: 29-39.
30. Bolignano D, Donato V, Laquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 2010;288:10-16.
31. Bousseouel S, Kauntz H, Gosse F, et al. Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. Int J Oncol 2010; 36:1485-1490.
32. Devarajan P. Neutrophil gelatinase-associated lipocalin: new path for an old shuttle. Cancer Ther 2007;5B:463-470.
33. Fernandez CA, Yan L, Louis G, Kutok JL, Moser MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005;11:5390-5395.
34. Villalva C, Sorel N, Bonnet ML, et al. Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia. Leuk Lymphoma 2008;49:984-988.
35. Nieborowska-Skorska M, Hoser G, Rink L, et al. Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells. Cancer Res 2006;66:4108-4116.
36. Miharada K, Hiroyama T, Sudo K, Nagasawa T, Nakamura Y. Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion. FASEB J 2005; 19:1881-1883.
37. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with side-rophore-mediated iron acquisition. Mol Cell 2002;10:1033-1043.
38. Li J-Y, Gita Ram G, Gast K, et al. Detection of intracellular iron by its regulatory effect. Am J Physiol Cell Physiol 2004;287:1547-1559.
39. Gazitt Y, Reddy SV, Alcantara O, Yang J, Boldt DH. A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myristate acetate. J Cell Physiol 2001; 187:124-135.
40. Malyszko J, Tesor U, Macdougall IC. Neutrophil gelatinase-associated lipocalin and hepcidin: what do they have in common and is there a potential interaction. Kidney Blood Press Res 2010;33:157-165.
41. Kwapisz J, Zekanowska E, Jasiniewska J. Decreased serum prohepcidin concentration in patients with polycythemia vera. J Zhejiang Univ Sci B 2009;10:791-795.
42. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 12 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis study. J Clin Oncol 2009;274:124-129.
43. Betschauer AP, Figueiredo CP, Bueno EC, et al. D-dimer as a possible prognostic marker of operable hormone receptor negative breast cancer. Ann Oncol 2010;21:1267-1272.
44. Blackwell K, Haroon Z, Broadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000;18: 600-608.